iVascular’s Luminor DCB for Femoropopliteal Disease Evaluated in LUMIFOLLOW Registry

March 18, 2026—iVascular announced 3-year follow-up results from the LUMIFOLLOW registry, a large real-world study evaluating the safety and efficacy of the Luminor paclitaxel drug-coated balloon (DCB) in the treatment of femoropopliteal artery disease.

Large Primary Care Study Outlines PAD Burden and Incidence in United States

January 28, 2026—In a retrospective cohort study examining patterns of peripheral artery disease (PAD) diagnosis in United States primary care settings, Nriagu et al identified substantial demographic, clinical, and socioeconomic disparities in PAD burden and observed a notable increase in PAD incidence following the COVID-19 pandemic.

Boston Scientific’s Seismiq Peripheral IVL System Introduced in Limited Market Release

January 22, 2026—Boston Scientific has initiated the limited market release of the Seismiq intravascular lithotripsy (IVL) system, marking the completion of the first peripheral cases using the device.

Serum cFAS Shows Promise as a Diagnostic Marker in PAD and CLTI

December 8, 2025—In a retrospective study evaluating circulating fatty acid synthase (cFAS) as a biomarker for peripheral artery disease (PAD), Abu-Amer et al found that elevated cFAS levels were independently associated with both PAD and chronic limb-threatening ischemia (CLTI), with higher concentrations correlating with greater disease severity.

Philips Expands Commercial Availability of LumiGuide Light-Based 3D Navigation Solution 

December 1, 2025—Royal Philips announced the expanded commercial availability of its LumiGuide device guidance across Europe and the United States.

FORWARD PAD Results Presented for J&J’s Shockwave Javelin Peripheral IVL Catheter 

November 11, 2025—Johnson & Johnson MedTech announced the 1-year results from the FORWARD PAD study of its Shockwave Javelin peripheral intravascular lithotripsy (IVL) catheter, a Forward IVL platform designed to modify calcified occlusive lesions in patients with peripheral artery disease (PAD).

SAFE-PAD Trial Final Report Finds No Increased Mortality With Drug-Coated Devices

November 11, 2025—In this retrospective cohort study designed to assess long-term safety outcomes of drug-coated devices (DCDs) versus non–drug-coated devices (NDCDs) for femoropopliteal revascularization, Kim et al found no evidence of a long-term mortality risk and observed similar rates of major amputation with a lower need for surgical revascularization.

Surmodics Pounce Thrombectomy Platform Evaluated in Sex-Specific Analysis of PROWL Registry

November 6, 2025—Surmodics, Inc. announced results from a sex-specific analysis of its ongoing PROWL registry evaluating real-world use of the Pounce thrombectomy platform to treat thromboembolic limb ischemia.

DISRUPT BTK II Confirms Durability and Safety of IVL for Complex BTK Disease

November 3, 2025—Johnson & Johnson MedTech announced 1-year results from the DISRUPT BTK II postmarket study, demonstrating sustained safety and effectiveness of the Shockwave peripheral intravascular lithotripsy (IVL) system for treating calcified below-the-knee (BTK) lesions in patients with peripheral artery disease (PAD).

Cagent Vascular Launches Larger Diameters of Serranator PTA Catheters

October 8, 2025—Cagent Vascular announced the United States commercial launch of 7- and 8-mm diameters of the Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter.

FastWave Names Leadership for Pivotal Trial of Artero Electric IVL System

September 30, 2025—FastWave Medical, a developer of intravascular lithotripsy (IVL), announced the appointment of the principal investigators and steering committee for the upcoming United States investigational device exemption pivotal trial of the company’s Artero peripheral electric IVL system.

Cook’s Advance Evero 18 Everolimus-Coated Balloon IDE Study Plan Approved by FDA

August 20, 2025—Cook Medical announced that the FDA has granted approval for the company to initiate an investigational device exemption (IDE) study of the Advance Evero 18 everolimus-coated percutaneous transluminal angioplasty balloon catheter.

Medtronic Focuses on Carotid Therapies, Thrombectomy, and BTK Disease; Exits AVF Creation

June 13, 2025—With a distribution agreement in place and an option to acquire Contego Medical, Medtronic’s peripheral vascular division kicked off 2025 with renewed investment in the carotid artery stenting (CAS) field.

BD Rotarex to Be Assessed in XTRACT Postmarket Registry

May 28, 2025—BD (Becton, Dickinson and Company) announced plans to initiate the XTRACT patient data registry for its Rotarex atherectomy system.

Cordis Selution SLR DEB Evaluated in Two Studies of Complex PAD Patients

April 24, 2025—Cordis announced new data from the SUCCESS PTA and SELUTION SFA Japan peripheral studies evaluating the company’s Selution SLR (sustained limus release) drug-eluting balloon (DEB).

Results Published From TRANSCEND Study of Surmodics SurVeil DCB

April 22, 2025—Surmodics, Inc. announced the publication of results from the TRANSCEND clinical trial.

FDA Clears Bolt Medical IVL System for ATK, Boston Scientific Closes Acquisition

April 3, 2025—Boston Scientific announced via social media that it has closed the acquisition of Bolt Medical, which recently gained FDA clearance of its intravascular lithotripsy (IVL) platform for the above-the-knee (ATK) indication.

REALDES Study Compares Zilver PTX and Eluvia Drug-Eluting Stents at 3 Years

March 27, 2025—Investigators seeking to compare real-world outcomes with drug-eluting stents (DES) in symptomatic femoropopliteal lesions have shared results from REALDES, a prospective multicenter observational study.

Endologix Detour System Reaches Treatment Milestone

March 20, 2025—Endologix LLC announced it has reached a milestone of 1,000 patients who have been treated with percutaneous transmural arterial bypass (PTAB) using the company’s Detour system.

VentureMed Names Jordan Knepper as CMO and Announces Study Results for Flex VP System

March 14, 2025—VentureMed Group, Inc., a medical device company focused on arteriovenous access and peripheral arterial disease, recently announced the appointment of Jordan Knepper, MD, as Chief Medical Officer.